Mistras, Martin join Viatris
Plus: Nassim Usman at the helm at Totus as it raises $66M series B round, and updates from Tourmaline, HKEX, CIRM, CorMedix and RiverVest
Viatris Inc. (NASDAQ:VTRS) hired Theodora “Doretta” Mistras to succeed CFO Sanjeev Narula, effective March 1, 2024. Mistras was managing director, healthcare investment banking at Citigroup Global Markets and Goldman Sachs & Co. LLC. Viatris also hired Philippe Martin as chief R&D officer, effective immediately. Martin was chief development & operations at BioAtla Inc. (NASDAQ:BCAB).
Nassim Usman became president and CEO of Totus Medicines Inc., which also announced a $66 million series B round led by DCVC Bio. Founding CEO Neil Dhawan became head of R&D while remaining CSO. Usman was president, CEO, and board member at Catalyst Biosciences Inc. Totus is developing TOS-358, a PI3Kα inhibitor for genetically defined cancer. North Pond Ventures, Camford Capital and the Regents of the University of Minnesota participated in the series B. ...